GGTLC1 and Fabry disease: According to a previous study in which participants with FD were administered YGJ for 8 weeks [13], diarrhea (seven cases), nausea (three cases), headache (three cases), increase in the level of gamma-glutamyl transpeptidase (two cases), epigastric pain (two cases), increase in the level of alanine aminotransferase (one case), abdominal bloating (one case), abdominal discomfort (one case), common cold (one case), tinnitus (one case), skin abnormal sensation (one case), oral abnormal sensation (one case), vertigo (one case), and urticaria (one case) were reported as adverse events.